Holen Sie sich die Stockscreener-App
3.23
0.31%
-0.01
Handel nachbörslich:
3.22
-0.010
-0.31%
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN
Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan
Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com
Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada
Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist
Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull
Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria
Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener
Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus
Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks
Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks
Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan
Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks
APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN
Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus
Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus
Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks
Aptevo Therapeutics Announces Reverse Stock Split - TipRanks
Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus
Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus
Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa
APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus
APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus
Aptevo reports high remission in AML patients with new drug - Investing.com Australia
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire
Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus
Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus
1.02%
1.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):